Metabolic deregulation is a key factor in cancer progression. Epigenetic changes and metabolic rewiring are intertwined in cancer. Deregulated epigenetic modifiers cause metabolic aberrations by targeting the expression of metabolic enzymes. Conversely, metabolites and cofactors affect the expression and activity of epigenetic regulators. Small molecules are promising therapeutic approaches to target the epigenetic-metabolomic crosstalk in cancer. Here, we focus on the interplay between metabolic rewiring and epigenetic landscape in the context of tumourigenesis and highlight recent advances in the use of small-molecule drug targets for therapy.
CITATION STYLE
Das, D., Karthik, N., & Taneja, R. (2022). Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer. In Subcellular Biochemistry (Vol. 100, pp. 523–555). Springer Science and Business Media B.V. https://doi.org/10.1007/978-3-031-07634-3_16
Mendeley helps you to discover research relevant for your work.